Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00738530
Registration number
NCT00738530
Ethics application status
Date submitted
19/08/2008
Date registered
20/08/2008
Date last updated
23/06/2016
Titles & IDs
Public title
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Query!
Scientific title
A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Avastin Plus Roferon Compared With Placebo Plus Roferon on Overall Survival and Tumor Assessment in Nephrectomised Patients With Metastatic Clear Cell Renal Cell Carcinoma
Query!
Secondary ID [1]
0
0
2004-000282-35
Query!
Secondary ID [2]
0
0
BO17705
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Renal Cell Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Kidney
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Bevacizumab [Avastin]
Treatment: Drugs - Interferon alfa 2a [Roferon]
Treatment: Drugs - Placebo
Experimental: Bevacizumab + IFN-Alfa-2A - Bevacizumab infusions will be administered every 2 weeks at a dose of 10 milligram per kilogram (mg/kg) for 52 weeks or until disease progression or unacceptable toxicity. Interferon alfa-2a (IFN-Alfa-2A) will be administered 3 times per week as a subcutaneous injection at a dose of 9 million international units (MIU) for 52 weeks or until disease progression or major toxicity.
Placebo Comparator: Placebo + IFN-Alfa-2A - Placebo matched with Bevacizumab infusions will be administered every 2 weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A will be administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
Treatment: Drugs: Bevacizumab [Avastin]
10 mg/kg IV every 2 weeks
Treatment: Drugs: Interferon alfa 2a [Roferon]
9 MIU SC 3 times/week
Treatment: Drugs: Placebo
IV every 2 weeks
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Who Died
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Baseline up to 4.25 years
Query!
Primary outcome [2]
0
0
Overall Survival (OS) Duration
Query!
Assessment method [2]
0
0
Duration of survival was defined as the time between the date of randomization and date of death due to any cause. Participants still alive at the time of analysis were censored at the date they were last known to be alive. Kaplan-Meier estimates were used for analysis.
Query!
Timepoint [2]
0
0
Baseline until death (up to 4.25 years)
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Disease Progression or Death
Query!
Assessment method [1]
0
0
Progressive disease was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions.
Query!
Timepoint [1]
0
0
Baseline until disease progression or death, whichever occurred first (assessed at baseline, Weeks 8, 16, 24, 32, 44, 56, 68 thereafter every 12 weeks up to week 104 and then every 6 months up to 4.25 years)
Query!
Secondary outcome [2]
0
0
Progression Free Survival (PFS) According to Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
Query!
Assessment method [2]
0
0
Progression-free survival was defined as the time between the date of randomization and the first date of documented progression or date of death due to any cause, whichever occurred first. Tumor assessment was performed using modified RECIST. Progressive disease was defined as at least a 20 percentage(%) increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions. Participants without an event were censored at the date of last follow-up for progression or date of last available tumor measurement if no follow-up assessment for progression was performed. Participants who were randomized but not exposed to study drug and had no further follow-up were censored on the day of randomization.
Query!
Timepoint [2]
0
0
Baseline until disease progression or death, whichever occurred first (assessed at baseline, Weeks 8, 16, 24, 32, 44, 56, 68 thereafter every 12 weeks up to week 104 and then every 6 months up to 4.25 years)
Query!
Secondary outcome [3]
0
0
Time to Progression (TTP) According to Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
Query!
Assessment method [3]
0
0
Time to progression was defined as the time between date of randomization and date of documented progression. Tumor assessment was performed using mRECIST. Progressive disease was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions. Participants without an event (including participants who died before progressive disease) were censored at the date of last follow-up for progression or date of last available tumor measurement if no follow-up assessment for progression was performed. Participants who were randomized but not exposed to study drug and had no further follow-up were censored on the day of randomization.
Query!
Timepoint [3]
0
0
Baseline until disease progression or death, whichever occurred first (assessed at baseline, Weeks 8, 16, 24, 32, 44, 56, 68 thereafter every 12 weeks up to week 104 and then every 6 months up to 4.25 years)
Query!
Secondary outcome [4]
0
0
Percentage of Participants With Treatment Failure
Query!
Assessment method [4]
0
0
Treatment failure is defined as insufficient therapeutic response (including disease progression), death, withdrawal of treatment due to adverse events or laboratory abnormality, or withdrawal of informed consent. Tumor assessment was performed using mRECIST. Progressive disease was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions.
Query!
Timepoint [4]
0
0
Baseline until disease progression or death, whichever occurred first (assessed at baseline, Weeks 8, 16, 24, 32, 44, 56, 68 thereafter every 12 weeks up to week 104 and then every 6 months up to 4.25 years)
Query!
Secondary outcome [5]
0
0
Time to Treatment Failure (TTF) According to Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
Query!
Assessment method [5]
0
0
Time to treatment failure was defined as the time between the date of randomization and the date of insufficient therapeutic response (including disease progression), death, withdrawal of treatment due to adverse events or laboratory abnormality, or withdrawal of informed consent. Tumor assessment was performed using mRECIST. Progressive disease was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions. Participants without an event were censored at the date of last tumor assessment or last treatment administration, whichever occurred last. Participants who were randomized but not exposed to study drug and had no further follow-up were censored on the day of randomization.
Query!
Timepoint [5]
0
0
Baseline until disease progression or death, whichever occurred first (assessed at baseline, Weeks 8, 16, 24, 32, 44, 56, 68 thereafter every 12 weeks up to week 104 and then every 6 months up to 4.25 years)
Query!
Secondary outcome [6]
0
0
Percentage of Participants With Objective Response According to mRECIST
Query!
Assessment method [6]
0
0
Objective response referred to participants with complete response (CR) or partial response (PR). CR: disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR: greater than or equal to (>=) 30% decrease in sum of the longest diameter (LD) of all target lesions taking as reference the screening sum LD. To be assigned a status of PR or CR, changes in tumor measurements had to be confirmed by repeat assessments that should have been performed no less than 4 weeks after the criteria for response were first met. Longer intervals as determined by the study protocol were also appropriate.
Query!
Timepoint [6]
0
0
Baseline until disease progression or death, whichever occurred first (assessed at baseline, Weeks 8, 16, 24, 32, 44, 56, 68 thereafter every 12 weeks up to week 104 and then every 6 months up to 4.25 years)
Query!
Secondary outcome [7]
0
0
Percentage of Participants With Best Overall Response According to Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
Query!
Assessment method [7]
0
0
Best response recorded from the start of treatment until disease progression. Based on assessment of CR, PR, stable disease (SD), or progressive disease (PD), according to mRECIST. CR: disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR: >=30% decrease under baseline of the sum of the LD of all target lesions. CR and PR persist on repeat imaging study at least 4 weeks after initial documentation. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Reference is the smallest sum LD. PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions and/or the unequivocal progression of existing non-target lesions.
Query!
Timepoint [7]
0
0
Baseline until disease progression or death, whichever occurred first (assessed at baseline, Weeks 8, 16, 24, 32, 44, 56, 68 thereafter every 12 weeks up to week 104 and then every 6 months up to 4.25 years)
Query!
Secondary outcome [8]
0
0
Change From Baseline in Karnofsky Performance Status
Query!
Assessment method [8]
0
0
Karnofsky performance score is used to quantify participant's general well-being and activities of daily life and participants were classified based on their functional impairment. Karnofsky performance score is 11 level score which ranges between 0 (death) to 100 (no evidence of disease). Higher score means higher ability to perform daily tasks.
Query!
Timepoint [8]
0
0
Baseline, Week 7, 15, 23, 31, 43
Query!
Eligibility
Key inclusion criteria
- metastatic renal cell cancer (clear cell type);
- nephrectomy;
- absence of proteinuria.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- prior systemic treatment for metastatic renal cell cancer;
- major surgical procedure, open biopsy or significant traumatic injury within 28 days
prior to study treatment start;
- presence of brain metastases or spinal cord compression;
- ongoing need for full dose anticoagulants;
- uncontrolled hypertension;
- clinically significant cardiovascular disease.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2004
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/09/2008
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
649
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Adelaide
Query!
Recruitment hospital [2]
0
0
- Brisbane
Query!
Recruitment hospital [3]
0
0
- Canberra
Query!
Recruitment hospital [4]
0
0
- Frankston
Query!
Recruitment hospital [5]
0
0
- Kurralta Park
Query!
Recruitment hospital [6]
0
0
- Melbourne
Query!
Recruitment hospital [7]
0
0
- Perth
Query!
Recruitment hospital [8]
0
0
- Sydney
Query!
Recruitment postcode(s) [1]
0
0
5011 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
5041 - Adelaide
Query!
Recruitment postcode(s) [3]
0
0
4006 - Brisbane
Query!
Recruitment postcode(s) [4]
0
0
2606 - Canberra
Query!
Recruitment postcode(s) [5]
0
0
3199 - Frankston
Query!
Recruitment postcode(s) [6]
0
0
5037 - Kurralta Park
Query!
Recruitment postcode(s) [7]
0
0
3128 - Melbourne
Query!
Recruitment postcode(s) [8]
0
0
6009 - Perth
Query!
Recruitment postcode(s) [9]
0
0
2031 - Sydney
Query!
Recruitment postcode(s) [10]
0
0
2139 - Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
Belgium
Query!
State/province [1]
0
0
Antwerpen
Query!
Country [2]
0
0
Belgium
Query!
State/province [2]
0
0
Bruxelles
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Wilrijk
Query!
Country [4]
0
0
Czech Republic
Query!
State/province [4]
0
0
Ceské Budejovice
Query!
Country [5]
0
0
Czech Republic
Query!
State/province [5]
0
0
Chomutov
Query!
Country [6]
0
0
Czech Republic
Query!
State/province [6]
0
0
Hradec Kralove
Query!
Country [7]
0
0
Czech Republic
Query!
State/province [7]
0
0
Plzen
Query!
Country [8]
0
0
Finland
Query!
State/province [8]
0
0
Tampere
Query!
Country [9]
0
0
Finland
Query!
State/province [9]
0
0
Turku
Query!
Country [10]
0
0
France
Query!
State/province [10]
0
0
Angers
Query!
Country [11]
0
0
France
Query!
State/province [11]
0
0
Bordeaux
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Caen
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Clermont Ferrand
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Grenoble
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Lille
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Limoges
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Lyon
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Marseille
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Nice
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Poitiers
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Saint Herblain
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Strasbourg
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Suresnes
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Toulouse
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Villejuif
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Berlin
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Darmstadt
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Hamburg
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Hannover
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Mannheim
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Marburg
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
München
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Planegg
Query!
Country [34]
0
0
Hungary
Query!
State/province [34]
0
0
Budapest
Query!
Country [35]
0
0
Hungary
Query!
State/province [35]
0
0
Szombathely
Query!
Country [36]
0
0
Israel
Query!
State/province [36]
0
0
Holon
Query!
Country [37]
0
0
Israel
Query!
State/province [37]
0
0
Ramat-gan
Query!
Country [38]
0
0
Israel
Query!
State/province [38]
0
0
Rehovot
Query!
Country [39]
0
0
Israel
Query!
State/province [39]
0
0
Tel Aviv
Query!
Country [40]
0
0
Israel
Query!
State/province [40]
0
0
Zerifin
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Livorno
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Milano
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Modena
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Napoli
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Perugia
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Roma
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Rozzano
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Torino
Query!
Country [49]
0
0
Netherlands
Query!
State/province [49]
0
0
Amsterdam
Query!
Country [50]
0
0
Netherlands
Query!
State/province [50]
0
0
Nijmegen
Query!
Country [51]
0
0
Norway
Query!
State/province [51]
0
0
Oslo
Query!
Country [52]
0
0
Norway
Query!
State/province [52]
0
0
Stavanger
Query!
Country [53]
0
0
Norway
Query!
State/province [53]
0
0
Trondheim
Query!
Country [54]
0
0
Norway
Query!
State/province [54]
0
0
Ålesund
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Bydgoszcz
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Krakow
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Lodz
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Olsztyn
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Tarnow
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Warszawa
Query!
Country [61]
0
0
Russian Federation
Query!
State/province [61]
0
0
Moscow
Query!
Country [62]
0
0
Russian Federation
Query!
State/province [62]
0
0
Obninsk
Query!
Country [63]
0
0
Russian Federation
Query!
State/province [63]
0
0
St Petersburg
Query!
Country [64]
0
0
Singapore
Query!
State/province [64]
0
0
Singapore
Query!
Country [65]
0
0
Spain
Query!
State/province [65]
0
0
Barcelona
Query!
Country [66]
0
0
Spain
Query!
State/province [66]
0
0
Granada
Query!
Country [67]
0
0
Spain
Query!
State/province [67]
0
0
Madrid
Query!
Country [68]
0
0
Spain
Query!
State/province [68]
0
0
Málaga
Query!
Country [69]
0
0
Spain
Query!
State/province [69]
0
0
Pontevedra
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Santander
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Valencia
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Zaragoza
Query!
Country [73]
0
0
Switzerland
Query!
State/province [73]
0
0
Basel
Query!
Country [74]
0
0
Switzerland
Query!
State/province [74]
0
0
Bern
Query!
Country [75]
0
0
Switzerland
Query!
State/province [75]
0
0
Geneve
Query!
Country [76]
0
0
Taiwan
Query!
State/province [76]
0
0
Chang Gung
Query!
Country [77]
0
0
Taiwan
Query!
State/province [77]
0
0
Kaohsiung
Query!
Country [78]
0
0
Taiwan
Query!
State/province [78]
0
0
Taichung
Query!
Country [79]
0
0
Taiwan
Query!
State/province [79]
0
0
Taipei
Query!
Country [80]
0
0
United Kingdom
Query!
State/province [80]
0
0
London
Query!
Country [81]
0
0
United Kingdom
Query!
State/province [81]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This 2-arm study will evaluate the efficacy and safety of Avastin versus placebo in
combination with Roferon as first-line treatment in participants with metastatic renal cell
cancer (clear cell type) who have had nephrectomy. The anticipated time of study treatment is
1-2 years, and the target sample size is greater than (>)500 individuals.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00738530
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00738530
Download to PDF